Medicure Inc. (CVE:MPH – Get Free Report) shares hit a new 52-week high during trading on Tuesday. The stock traded as high as C$2.84 and last traded at C$2.84, with a volume of 400 shares traded. The stock had previously closed at C$2.72.
Medicure Trading Up 4.4%
The company has a debt-to-equity ratio of 6.02, a current ratio of 0.97 and a quick ratio of 1.28. The business’s 50-day moving average is C$1.85 and its two-hundred day moving average is C$1.39. The firm has a market cap of C$29.64 million, a P/E ratio of -3.94 and a beta of 0.93.
Medicure Company Profile
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
Further Reading
- Five stocks we like better than Medicure
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
- Tesla’s Semi Is Finally Here—But Will It Move the Stock?
- 5 Stocks Showing Why Pricing Power Matters More Than Government Money
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
